SBRT in the Management of Solid Spinal Metastases
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Apr 23, 2021
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called Stereotactic Body Radiation Therapy (SBRT) for patients who have cancer that has spread to the spine and is causing pressure on the spinal cord. The goal is to see how effective SBRT is in managing these spinal metastases, which can lead to serious problems like pain or loss of movement. The trial is currently looking for participants who are adults aged 18 and older, have a confirmed diagnosis of spinal metastasis from a solid tumor, and may be facing surgery or only receiving SBRT if surgery isn’t possible.
Participants in this study will receive either surgery followed by SBRT or just SBRT alone, depending on their specific situation. Before joining, they must give their written consent, meaning they agree to take part in the study after understanding what it involves. It’s important to note that individuals with certain other health conditions or those who have received radiation treatment on the same spinal area previously may not be eligible. Overall, this trial aims to provide valuable information about how well SBRT can help manage spinal tumors and improve patients' quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Radiological diagnosis of spinal metastasis from solid tumor with epidural imminent or actual spinal cord compression, with or without neurological deficits. Patients will be scheduled for surgery + SBRT. If contra-indications preclude surgery and only SBRT is performed, patients will still be included.
- • Written informed consent to participate in the study must be obtained from the subject or proxy /legal representative
- • Males and females \> 18 years
- Exclusion Criteria:
- • Any concomitant condition or disease which, in the opinion of the investigator, would affect the reliability of the collected data.
- • Patients that had previous radiotherapy on the index spinal level without the possibility for additional SBRT at that particular level.
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Bart Depreitere, MD, PhD
Principal Investigator
UZ Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials